Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to damage signals such as amyloid accumulation. When the process starts, the initial microglial response can be protective. However, in later stages, this response becomes dysfunctional and contributes to disease progression. At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), scientists focused on TREM2, a microglial receptor that regulates immune responses, exploring new ways to address neuroinflammation. Read More
Researchers from Chengdu Kanghua Biological Products Co. Ltd. recently published information on their novel varicella zoster virus (VZV) mRNA vaccine candidate (KH014). KH014 contains sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in ionizable lipid nanoparticles. Read More
Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease Read More
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and oligomer stability, and may reduce both intracellular and extracellular amyloid-β aggregates in the brain. Amlogenyx Inc. has presented data regarding their approach based on PPCA delivery through an adenoviral vector (AAV9), namely AM-805, for the potential treatment of Alzheimer’s disease (AD). Read More
Bolt Biotherapeutics Inc. has prepared and tested new immunoconjugates comprising antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists. They are designed for potential use in the treatment of cancer. Read More
CAR T-cell therapy can be applied to treat some chronic infectious diseases, particularly to provide a functional cure for HIV-1 in people living with HIV. However, the effectiveness of CAR T cells for persistent suppression of HIV still faces many constraints, including the high mutation rate of reverse transcriptase, which enables the emergence of immune escape viral variants. Read More
Sichuan Primed Shines Bio-Tech Co. Ltd. researchers have published results on their investigation regarding SYW-06 oral dosing and its impact on cognitive function in monkeys submitted to middle-cerebral artery occlusion (MCAO). Read More
The Scripps Research Institute has discovered new bicyclo[1.1.1]pentane-based DNA topoisomerase inhibitors and antibody-drug conjugates comprising a monoclonal antibody covalently linked to a DNA topoisomerase inhibitor. They are described as potentially useful for the treatment of cancer. Read More
Researchers from GSK plc and collaborators described the identification of MMV-1581361, a PfATP4 inhibitor, and its efficacy in models of malaria. The compound originates from MMV-020136, following structure-activity relationship studies to optimize antimalarial activity. Read More
Ensem Therapeutics Inc. has divulged new bicyclic heteroaryl and heterocyclic compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer. Read More
Uppthera Inc. has patented new NLRP3 inflammasome inhibitors potentially useful for the treatment of cancer, metabolic and autoimmune diseases, cardiovascular, inflammatory, neurological, renal and respiratory disorders, among others. Read More
Researchers from the Chinese Academy of Sciences reported the design and preclinical characterization of YCH-3971, a selective PARP1 inhibitor developed for the treatment of BRCA-mutated tumors. Read More
